Show simple item record

dc.contributor.authorBeltrán Camacho, Lucía 
dc.contributor.authorJiménez Palomares, Margarita 
dc.contributor.authorSánchez Gomar, Ismael 
dc.contributor.authorRosal Vela, Antonio 
dc.contributor.authorRojas Torres, Marta 
dc.contributor.authorEslava Alcón, Sara 
dc.contributor.authorAlonso Piñero, José Ángel
dc.contributor.authorGonzález Rovira, Almudena 
dc.contributor.authorExtremera García, Mª Jesús
dc.contributor.authorConejero, Rosario
dc.contributor.authorDoiz Artázcoz, Esther 
dc.contributor.authorRodríguez Piñero, Manuel
dc.contributor.authorRøssel Larsen, Martin
dc.contributor.authorDurán Ruiz, María del Carmen 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.contributor.otherCirugíaes_ES
dc.date.accessioned2021-12-10T11:38:47Z
dc.date.available2021-12-10T11:38:47Z
dc.date.issued2021-09
dc.identifier.issn2227-9059
dc.identifier.urihttp://hdl.handle.net/10498/25840
dc.description.abstractCritical limb ischemia (CLI), the most severe form of peripheral artery disease, results from the blockade of peripheral vessels, usually correlated to atherosclerosis. Currently, endovascular and surgical revascularization strategies cannot be applied to all patients due to related comorbidities, and even so, most patients require re-intervention or amputation within a year. Circulating angiogenic cells (CACs) constitute a good alternative as CLI cell therapy due to their vascular regenerative potential, although the mechanisms of action of these cells, as well as their response to pathological conditions, remain unclear. Previously, we have shown that CACs enhance angiogenesis/arteriogenesis from the first days of administration in CLI mice. Also, the incubation ex vivo of these cells with factors secreted by atherosclerotic plaques promotes their activation and mobilization. Herein, we have evaluated the long-term effect of CACs administration in CLI mice, whether pre-stimulated or not with atherosclerotic factors. Remarkably, mice receiving CACs and moreover, pre-stimulated CACs, presented the highest blood flow recovery, lower progression of ischemic symptoms, and decrease of immune cells recruitment. In addition, many proteins potentially involved, like CD44 or matrix metalloproteinase 9 (MMP9), up-regulated in response to ischemia and decreased after CACs administration, were identified by a quantitative proteomics approach. Overall, our data suggest that pre-stimulation of CACs with atherosclerotic factors might potentiate the regenerative properties of these cells in vivo.es_ES
dc.description.sponsorshipThis study was supported by the Institute of Health Carlos III, ISCIII (PI16-00784, PI2000716), co-funded by European Regional Development Fund "A way to make Europe", and the Programa Operativo de Andalucia FEDER, Iniciativa Territorial Integrada ITI 2014-2020, Consejeria de Salud, Junta de Andalucia (PI0026-2017).es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceBiomedicines 2021, 9(9), 1147es_ES
dc.subjectCirculating angiogenic cellses_ES
dc.subjectcritical limb-threatening ischemiaes_ES
dc.subjectatherosclerotic secretomees_ES
dc.subjectproteomicses_ES
dc.subjectneovascularizationes_ES
dc.subjectimmune cellses_ES
dc.titleLong Term Response to Circulating Angiogenic Cells, Unstimulated or Atherosclerotic Pre-Conditioned, in Critical Limb Ischemic Micees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/biomedicines9091147
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI16%2F00784/ES/Validación de biomarcadores y Terapia celular alternativa en Aterosclerosis basada en la modulación de células endoteliales progenitoras y células T reguladoras/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI20/00716/ES/COMPLICACIONES VASCULARES EN DIABETES MELLITUS: APLICACIÓN DE ESTRATEGIAS PROTEÓMICAS PARA POTENCIAR EL DESARROLLO DE TERAPIAS MOLECULARES/CELULARES ESPECÍFICAS PARA CADA PACIENTE/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Andalucía//PI0026-2017es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional